Bladder Cancer

Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances. July 15, 2026

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract July 14, 2026

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy - Beyond the Abstract July 14, 2026

Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study. July 14, 2026

Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer. July 13, 2026

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility July 10, 2026

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials. July 10, 2026

Diagnosis, Evaluation, and Management of Patients with Non-Muscle Invasive Bladder Cancer - Beyond the Abstract July 9, 2026

The impact of cachexia and sarcopenia in bladder cancer. July 9, 2026

Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience - Beyond the Abstract July 8, 2026

Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study. July 15, 2026

Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the Abstract July 14, 2026

Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy. July 14, 2026

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS). July 14, 2026

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study. July 13, 2026

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. July 10, 2026

Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study. July 10, 2026

Beyond the bladder: case series of Mycobacterium bovis bacillus Calmette-Guérin infections following intravesical instillation. July 9, 2026

Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer. July 9, 2026

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study. July 8, 2026

Page 1 of 606